{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-003054","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.606013+00:00","generated_at":"2026-05-27T22:30:28.627414+00:00","sec_items":["1.01","5.02","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Mangoceuticals converts $150K note into 100K shares; appoints Antonios Isaac as President & Director","bullets":["Debt conversion with Mill End Capital: $150K promissory note converted to 100K restricted common shares at $1.50/share.","Antonios Isaac appointed as Director and President; enters 12-month consulting agreement at $10K/month.","Final 250 shares of Series B Preferred Stock sold for $250K, completing Fourth Closing under 2024 SPA.","Conversion of note triggers anti-dilution repricing: all outstanding warrants and Series B conversion price adjusted to $1.50/share."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-003054","json":"https://secwatch.observer/filing/0001493152-25-003054.json","markdown":"https://secwatch.observer/filing/0001493152-25-003054.md","text":"https://secwatch.observer/filing/0001493152-25-003054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315225003054/0001493152-25-003054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315225003054/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T22:30:28.627414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d120de58a","claim":"Antonios Isaac was appointed as President at MANGOCEUTICALS, INC..","evidence_excerpt":"appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938046/000149315225003054/0001493152-25-003054-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"bdf6d73547","claim":"Antonios Isaac was appointed as Director at MANGOCEUTICALS, INC..","evidence_excerpt":"appointed Antonios Isaac as a member of the Board and as President of the Company, which appointments were effective the same day.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938046/000149315225003054/0001493152-25-003054-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}